Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a woman with trichotillomania who experienced marked improvement and hair regrowth after off-label onabotulinumtoxinA treatment.

This article discusses the use of low-dose oral minoxidil as an off-label treatment for androgenetic alopecia but reports no new clinical results.

In this study, ritlecitinib 50-mg showed clinically meaningful efficacy, with improvements in the Severity of Alopecia Tool score observed in patients with alopecia areata over a 3-year period, demonstrating long-term benefit in both clinician- and patient-reported outcomes.

In this report, the author shares experiences from a six-month curricular internship, highlighting activities such as arterial pressure monitoring in a community pharmacy and addressing off-label rituximab use at a hospital, alongside discussions of hair loss treatments and nutritional supplementation for dysphagia in the elderly.

This review discusses the implications of renaming myelodysplastic syndromes as "myelodysplastic neoplasms" and argues that the "low-risk" label may misrepresent patient experiences and hinder research.

In this retrospective study conducted at a trichology clinic, the off-label use of upadacitinib for at least 24 weeks was found to have a promising efficacy and safety profile for treating severe alopecia areata in adolescents.

This study found that a combination of topical and oral treatment led to greater improvements in hair density, thickness, and anagen/telogen ratio in patients with androgenetic alopecia compared to topical treatment alone, with significant benefits observed over a 3-month period.

In this case study, a neutered British Shorthair cat with diabetes mellitus showed fast remission of facial skin issues using off-label oclacitinib, with no recurrence for 17 months, but required surgery for eyelid cicatrization.

This source reports that combining 5-alpha reductase inhibitors with minoxidil for treating male androgenic alopecia presents a minimal risk of side effects when administered following established medical guidelines, with finasteride commonly associated with reversible sexual side effects and dutasteride used off-label with similar risks.

This source suggests that oral minoxidil could be a safe and effective treatment option for both female and male androgenetic alopecia, although it is currently used off-label.

This study describes the use of a genetically engineered mouse model, mTurquoise2-Col4a1, to fluorescently label collagen IV and observe basement membrane dynamics during skin development, revealing its stability and pliability during rapid growth phases.

This study reviewed information from various sources to highlight the versatile uses of botulinum toxin beyond aesthetic treatments, noting its successful application in fields like neurology, urology, and psychiatry, while also emphasizing its off-label therapeutic potential.

This study discusses treatment options for androgenetic alopecia, highlighting that while available therapies include approved and off-label pharmacological agents and non-pharmacological treatments, there is still limited evidence-based guidance on managing this common hair loss disorder.

This study found that a significant portion of counterfeit drugs seized among bodybuilders did not match their labels, with many containing undeclared anabolic steroids or other unexpected active ingredients.

This study analyzed adverse event reports from the FDA Adverse Event Reporting System and identified new side effects of topical minoxidil, such as application site acne and cysts, which are not well-documented on product labels, suggesting a need for updated safety information.

This study found that among bodybuilder-intended drugs from the black market, 33.8% of labeled products and 52.5% of steroidal oily solutions contained ingredients not matching their labels.

This study revealed significant signals of drug-related cognitive disorders in several medications that lack relevant FDA label warnings, suggesting a need for increased clinical awareness and potential label updates.

In this narrative review, researchers found preliminary evidence suggesting that minoxidil, both topical and oral, may enhance nail growth and improve nail strength and appearance, though more extensive studies are needed to confirm its efficacy and safety for this off-label use.

This study found that a food supplement improved skin moisturization, elasticity, and thickness, reduced telogen hair density, and enhanced nail status in women with mild-to-moderate aging signs after 84 days.

This source reports that an international panel of dermatologists has provided a consensus statement to guide clinicians on the off-label use of low-dose oral minoxidil for treating hair loss.

This study found that Dr. SKS Hair Booster Serum significantly improved hair shaft diameter, terminal hair counts, and hair growth rate in women with PCOS experiencing female pattern hair loss, without any reported adverse events, over a six-month treatment period.

This study reviews methods to ensure the reliability of machine learning models in medical imaging, focusing on bias detection, data drift assessment, and accuracy estimation without ground truth labels to enhance integration into clinical settings.

In this study, researchers identified significant signals indicating previously unrecognized risks of lipid metabolism abnormalities for several drugs, urging the need for better monitoring and label updates.

This study observed that among UK alopecia areata patients seeking JAK inhibitor treatments before public funding, many sourced medication from abroad due to high costs, with variable response rates and significant reliance on social media for information on accessing treatments.

In this open-label study, participants reported that the LustrivaTM BH-002 two-step system improved various aspects of hair, skin, and nail health and appearance after three months of use.

This study established a protocol using anti-steroid antibodies to differentially label epidermal cell contributors, suggesting potential applications in simplifying complex trace DNA mixtures before profiling.

In this study, a specially adapted nonablative radiofrequency device significantly increased hair growth measures in most patients with androgenetic alopecia, including hair count and density.

In this study, neoadjuvant treatment with durvalumab combined with albumin-bound paclitaxel and carboplatin in patients with driver gene-negative stage III NSCLC showed a 65% objective response rate and was associated with high pathological response rates and improved immune function, with most adverse events being mild.

This study reported that Ell-Cranell® alpha 0.025% solution significantly increased hair counts and diameter in Korean women with female pattern hair loss over an 8-month period, showing both efficacy and safety.

This article reviews the literature on the off-label use of botulinum toxin for dermatological conditions, highlighting its potential effectiveness in treating rosacea, anal fissures, Raynaud phenomenon, hypertrophic scars, keloids, and hidradenitis suppurativa.